Multiple sclerosis drug on fast track
Biogen Idec Inc., a Cambridge company known for its multiple sclerosis drugs, said the US Food and Drug Administration has granted it fast-track designation for a potential treatment of relapsing multiple sclerosis.
The company refers to its drug candidate as PEGylated interferon beta-1a, or BIIB017, and said in a release the fast-track program “is designed to expedite the review of new drugs that are intended to treat serious or life-threatening conditions and demonstrate the potential to address unmet medical needs.’’
Biogen Idec said it is currently enrolling patients in a global Phase III study evaluating the efficacy and safety of either biweekly or once-monthly injections of the drug.
© Copyright 2009 Globe Newspaper Company.
